approvalsWatch: Neurology 130716
US FDA Approvals
The US FDA has approved ExAblate Neuro, the first focused ultrasound for the treatment of essential tremor in patients nonresponsive to medication. The technique uses focused ultrasound waves to target and destroy brain tissue under magnetic resonance imaging guidance. The approval was made based on data from a randomised trial of 76 patients with essential tremor, 56 of whom received ExAblate Neuro treatment and experienced a 50% improvement after 3 months. This compared with no improvement or slight worsening in the patients receiving sham treatment.